First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
/PRNewswire/ -- Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2...
United States David Sallman Aaron Schuler John Zebala H Lee Moffitt Cancer Center Syntrix Pharmaceuticals
Source: prnewswire.com